Formulations for amylin agonist peptides

Abstract

The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. This formulation may be in liquid, gel, solid or powdered form for delivery, for example, via nasal, pulmonary, oral, sublingual, buccal, transdermal, or parenteral routes. Formulation with biocompatible polymers and release modifiers, such as sugars, can facilitate controlled release after injection, minimizing the number of administrations to a patient. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin for administration to a patient.

Description

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS[0001]This application is a continuation of U.S. Ser. No. 10 / 159,779, filed May 31, 2002, now issued as U.S. Pat. No. 7,312,196, which in turn is a continuation in part of U.S. Ser. No. 09 / 005,262, filed Jan. 9, 1998, now issued as U.S. Pat. No. 6,401,511, the contents of which are hereby incorporated by reference in their entirety.FIELD OF INVENTION[0002]This invention relates to pharmaceutical formulations of amylin agonist peptides, particularly in solid, suspension and liquid formulations. Additionally, this invention relates to amylin agonist pharmaceutical formulations which are compatible upon mixing with insulin or are prepared to allow co-administration with insulin or other therapeutic or antidiabetic compositions.BACKGROUND OF THE INVENTION[0003]Deposition of amyloid in pancreatic islets is a common feature in human Type II diabetic patients. The major protein forming these amyloid particles, called amylin, has a propensity to...

AI Technical Summary

Benefits of technology

[0017]It has been found that this novel parenteral dosage form surprisingly maintains the stability of the peptide for up to four years at refrigerated temperatures, e.g., approximately 5° C., and over 30 days at room temperature, e.g., approximately 30° C.

[0018]The inventors have further discovered that the above described pharmaceutical formulation can be further mixed with insulin product and retain short term stability. This mixture may occur, e.g., in a syringe. This short term mixing compatibility is extremely advantageous. This allows administration of a single injection of an amylin agonist, or amylin, along with insulin to a patient.

[0020]A further aspect of the invention features a formulation including an amylin agonist, mixed with a stabilizing compound which reduces loss of biological potency of the peptide in, for example, an amylin specific receptor binding assay, reduces loss of biological activity as measured in, for example, the in vitro soleus muscle bioassay, and general loss of material by, for example, an HPLC assay, as compared to a formulation consisting of the amylin alone.

[0021]In a related aspect, the invention features a method for formulating amylin agonists that retain short term (e.g., up to 24 hours) mixing compatibility with insulin. Certain insulins, such as insulin glargine (Lantus™), may allow for longer term stability (the term “insulin,” as used in the presently described formulations, refers to various types of insulins including, for example, insulin glargine).

Problems solved by technology

Sulfonylureas are the primary oral antihyperglycemic diabetic medications sold in the U.S. Discovered in the 1940's, these compounds do not address the underlying causes of Type II diabetes and, in many cases, are not effective or lose their efficacy after a few years of treatment.

Type II diabetics do not lack insulin, rather they are insulin resistant, so that insulin does not work properly and the insulin secretory responses are disordered.

Deficiency of an important hormone such as amylin which has been reported to have effects on carbohydrate, fat and bone metabolism, may also disrupt other important physiological mechanisms.

Any changes in physical appearance such as color changes or haziness can cause a patient or consumer to lose confidence in the product.

A cloudy solution or a broken emulsion can lead to a non-uniform dosage pattern.

Third, the active ingredient must be available to the patient throughout the expected shelf life of the preparation.

A breakdown of the product to inactive or otherwise undesired forms can lead to non-availability of the medicament to the patient.

Small peptides are typically unstable and are susceptible to degradation in aqueous solution.

In this regard, once a human amylin agonist or amylin has less than approximately 90% of its labeled potency, it is no longer considered to be suitable for administration to a patient.

Images